REVIEW
Stage IIIA NSCLC with limited N2 disease: Ιnduction chemotherapy and reseption or surgical treatment and adjuvant chemotherapy?
 
More details
Hide details
1
Thoracic Surgery Clinic, Hospital for Diseases of the Chest “SOTIRIA”
 
2
4th Department of Pneumonology, Hospital for Diseases of the Chest “SOTIRIA”
 
3
Nursing Department, Hospital for Diseases of the Chest “SOTIRIA”
 
4
Oncology Unit, 3rd Department of Athens School of Medicine, Hospital for Diseases of the Chest “SOTIRIA”
 
 
Pneumon 2015;28(1):87–94
 
KEYWORDS
 
REFERENCES (46)
1.
Siegel R, Naishadham D, Jemal A. Cancel statistics, 2012. CA Cancer J Clin 2012;62:10-29.
 
2.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
 
3.
van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and MIA. Chest 2000;117:374-379.
 
4.
Fang D, Zhang D, Huang G, Zhang R, Wang L, Zhang D. Results of surgical resection of patients with primary lung cancer: a retrospective analysis of 1,905 cases. Ann Thorac Surg 2001;72:1155-1159.
 
5.
Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994;86:673-680.
 
6.
Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998;21:1-6.
 
7.
Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994;330:153-158.
 
8.
Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999;26:7-14.
 
9.
Depierre A, Milleron B, Moro-Sibilot D, et al; French Thoracic Cooperative Group. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIia non-small-cell lung cancer. J Clin Oncol 2002;20:247-253.
 
10.
Burdett S, Stewart LA, Rydzewska L. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 2006;1:611.
 
11.
Lim E, Harris G, Patel A, Adachi I, Edmonds L, Song F. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol 2008;3.S56(Abstr 1500).
 
12.
Van Schil P, Van Meerbeeck J, Kramer G, et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J 2005;26:192-197.
 
13.
Betticher DC, Hsu Schmitz SF, Totsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006;94:1099-1106.
 
14.
De Marinis F, Nelli F, Migliorino MR, et al. Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage HIA(N2) non-small cell lung carcinoma: a Phase II multicenter study. Cancer 2003;98:1707-1715.
 
15.
O’ Brien ME, Splinter T, Smit EF, et al, EORTC Lung Cancer Group. Carboplatin and paclitaxel (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer, an EORTC phase II stydy (EORTC 08958). Eur J Cancer 2003;39:1416-1422.
 
16.
Cappuzzo F, Selvaggi G, Gregorc V, et al. Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage HIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study. Cancer 2003;98:128-134.
 
17.
Biesma B, Manegold C, Smit H J, et al; EORTC Lung Cancer Group. Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer: a phase II study of the European Organization foe research and treatment of cancer (EORTC 08984). Eur J Cancer 2006; 42:1399-1406.
 
18.
Garrido P, Gonzalez-Larrida JL, Insa A, et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and HIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. J Clin Oncol 2007;25:4736-4742.
 
19.
Berghmas T, Paesmans M, Meert AP, et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005;49:13-23.
 
20.
Grunenwald DH, Albain KS. The potential role of surgery after induction treatment. Semin Radiat Oncol 2004;14:335-339.
 
21.
Doddoli C, Barlesi F, Trousse D, et al. One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg 2005;130:416-425.
 
22.
Van Schil P, Kramer G, et al. Morbidity and mortality in the surgery arm of EORTC 08941 trial. Eur Respir J 2005;26:192-197.
 
23.
Fernando HC, Goldstraw P. The accuracy of clinical evaluative intrathoracic staging. Cancer 1990;65:2503-2506.
 
24.
Ginsberg RJ. Multimodality therapy for stage NIA (N2) lung cancer: an overview. 1993;103:356S-359S.
 
25.
Van Klaveren RJ, Often HG, Cox AL, et al. Prognosis of unsuspected but completely resectable N2 non-small cell lung cancer. Ann Thorac Surg 1993; 56:300-304.
 
26.
Watanabe Y, Shimizu J, Hayashi Y, et al. Results of surgical treatment on patients with stage MA non-small cell Lung cancer. J Thorac Cardiovasc Surg 1991;39:44-49.
 
27.
Maggi GC, Mancuso M, Oliaro A, et al. Resection and radical lymphadenectomy for lung cancer: prognostic significance of lymphatic metastases. Int Surg 1990; 75:17-21 (27L).
 
28.
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311(7010):899-909.
 
29.
Scagliotti GV, Fossati R, Torri V, et al; Adjuvant Lung Project Italy/Eyropean Organization for Research Treatment of CancerLung Cancer Cooperative Group Investigators. Randomized study of adjuvant chemotherapy for completely resected stage I, II or MA non-small-cell Lung cancer. J Natl Cancer Ins 2003;95:1453-1461.
 
30.
Waller D, Peake MD, Stephens RJ, et al. Chemotherapy for patients with non-small-cell Lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg 2004;26:173-182.
 
31.
Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell Lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]: a randomized controlled trial. Lancet Oncol 2006;7:719-727.
 
32.
Le Chevalier T, Dunant A, Arriagada R, et al, IALT Collaborative Group. Long-term results of the international Adjuvant Lung Cancer Trial (IALT) evaluating adjuvant cisplatin-based chemotherapy in resected non-small-cell lung cancer (NSCLC). J Clin Oncol 2008; 26: (May 20 suppl;abstr 7507).
 
33.
Pignon JP, Tribodet H, Scagliotti GV, et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552- 3559.
 
34.
Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J; International Adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
 
35.
Winton T, Livingston R, Johnson D, et al; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR. 10 Trial Investigators. Vinorelbine plus cisplatin vs.
 
36.
Solomon B, Bunn PA Jr. Adjuvant chemotherapy for non-smallcell lung cancer. Cancer Invest 2007;25:217-225.
 
37.
Strauss GM, Herndon J, Maddaus MA, et al. Randomized Clinical Trial of adjuvant chemotherapy with paclitaxei and carboplatin following resection in Stage IB non-small-cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. ASCO Annual Meeting Proceedings. J Clin Oncol 2004; 22:7019.
 
38.
Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 2010;28:3138.
 
39.
Hamada C, Tanaka F, Ohta M, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005;23:4999-5006.
 
40.
Stewart LA, Burdett S, Tierney JF, et al. Surgery and adjuvant chemotherapy (CT) compared to surgery alone in non-small-cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomized clinical trials (RCT). ASCO Annual Meeting Proceedings. J Clin Oncol 2007;25:7552.
 
41.
Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable in non-small-cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomized trial and update of systematic review. Lancet2007; 369:1929-1937.
 
42.
Potti A, Mukherjee S, Petersen R, et al. Agenomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-580.
 
43.
Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol 2005;23:3219-3226.
 
44.
Ju Z, Kapoor M, Newton K, et al. Global detection of molecular changes reveals concurrent alteration of several biological pathways in non-small-cell lung cancer cells. Mol Genet Genomics 2005; 274:141-154.
 
45.
13th World Conference on Lung Cancer (WCLC): Abstact PRS.3. Presented August 3, 2009.
 
46.
ASCO Meeting Abstracts, Aug 18, 2008: 18504.
 
eISSN:1791-4914
ISSN:1105-848X